-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Pyrazoles are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Pyrazoles.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR
(2002) Lancet 360: 1071-3 - Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.
Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS
(2007) Nature 447: 959-65 - Targeting Plasmodium PI(4)K to eliminate malaria.
McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TS, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Nagle A, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA
(2013) Nature 504: 248-253 - Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W
(2014) Nat Med 20: 1027-34 - BMP type I receptor inhibition reduces heterotopic [corrected] ossification.
Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, Kamiya N, Fukuda T, Mishina Y, Peterson RT, Bloch KD
(2008) Nat Med 14: 1363-9 - ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ
(2012) J Clin Oncol 30: 863-70 - Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN
(2016) J Clin Oncol 34: 123-9 - Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.
Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR
(2001) Circulation 104: 820-5 - Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT
(2008) Nat Chem Biol 4: 33-41 - Antimetastatic role of Smad4 signaling in colorectal cancer.
Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK
(2010) Gastroenterology 138: 969-80.e1-3 - Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB
(2015) Gastroenterology 149: 1932-1943.e9 - Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN
(2001) Gastroenterology 120: 1713-9 - A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells.
Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ, DuBois RN, Beauchamp RD
(1997) Gastroenterology 113: 1883-91 - TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL
(2013) J Clin Invest 123: 1348-58 - Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells.
Hao CM, Yull F, Blackwell T, Kömhoff M, Davis LS, Breyer MD
(2000) J Clin Invest 106: 973-82 - Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN
(1997) J Clin Invest 99: 2254-9 - BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction.
Sanders LN, Schoenhard JA, Saleh MA, Mukherjee A, Ryzhov S, McMaster WG, Nolan K, Gumina RJ, Thompson TB, Magnuson MA, Harrison DG, Hatzopoulos AK
(2016) Circ Res 119: 434-49 - Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.
Lovly CM, Pao W
(2012) Sci Transl Med 4: 120ps2 - Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA
(2013) Cancer Discov 3: 430-43 - Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL
(2019) Nat Commun 10: 1373 - Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression.
Carrier EJ, Auchampach JA, Hillard CJ
(2006) Proc Natl Acad Sci U S A 103: 7895-900 - Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ
(2005) Proc Natl Acad Sci U S A 102: 11011-6 - Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.
Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD
(1997) Proc Natl Acad Sci U S A 94: 657-62 - Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.
Li C, Singh B, Graves-Deal R, Ma H, Starchenko A, Fry WH, Lu Y, Wang Y, Bogatcheva G, Khan MP, Milne GL, Zhao S, Ayers GD, Li N, Hu H, Washington MK, Yeatman TJ, McDonald OG, Liu Q, Coffey RJ
(2017) Proc Natl Acad Sci U S A 114: E2852-E2861 - Mechanisms underlying the activation of G-protein-gated inwardly rectifying K+ (GIRK) channels by the novel anxiolytic drug, ML297.
Wydeven N, Marron Fernandez de Velasco E, Du Y, Benneyworth MA, Hearing MC, Fischer RA, Thomas MJ, Weaver CD, Wickman K
(2014) Proc Natl Acad Sci U S A 111: 10755-60 - Activation of heme biosynthesis by a small molecule that is toxic to fermenting Staphylococcus aureus.
Mike LA, Dutter BF, Stauff DL, Moore JL, Vitko NP, Aranmolate O, Kehl-Fie TE, Sullivan S, Reid PR, DuBois JL, Richardson AR, Caprioli RM, Sulikowski GA, Skaar EP
(2013) Proc Natl Acad Sci U S A 110: 8206-11 - Ventricular arrhythmias and sudden death in patients taking ibrutinib.
Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR
(2017) Blood 129: 2581-2584 - Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats.
Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, Willenbacher W, Eller K, Wolf D, Seifert M, Sun CC, Babitt JL, Hong CC, Menhall T, Gearing P, Lin HY, Weiss G
(2011) Blood 118: 4977-84 - Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.
Cheng H, Fan X, Moeckel GW, Harris RC
(2011) J Am Soc Nephrol 22: 1240-51 - Applications of small molecule BMP inhibitors in physiology and disease.
Hong CC, Yu PB
(2009) Cytokine Growth Factor Rev 20: 409-18 - The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat.
Petrie KA, Bubser M, Casey CD, Davis MD, Roth BL, Deutch AY
(2004) Neuropsychopharmacology 29: 1878-88 - Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.
Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S, Morrow JD, Dubois RN, Dey SK
(2007) Cancer Res 67: 5285-92 - Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.
Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN
(2000) Cancer Res 60: 6045-51 - Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN
(1998) Cancer Res 58: 362-6 - Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells.
Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD
(1998) Cancer Res 58: 2323-7 - A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
Wang JL, Cheng HF, Shappell S, Harris RC
(2000) Kidney Int 57: 2334-42 - Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.
Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC
(2002) Kidney Int 62: 929-39 - Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development.
Kömhoff M, Wang JL, Cheng HF, Langenbach R, McKanna JA, Harris RC, Breyer MD
(2000) Kidney Int 57: 414-22 - Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK
(2012) Clin Cancer Res 18: 4682-90 - ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK
(2011) Clin Cancer Res 17: 7394-401
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
